BioCentury
ARTICLE | Clinical News

Lilly debuts data for new Type II diabetes candidate

October 5, 2018 7:12 PM UTC

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase IIb trial in Type II diabetics showing that high-dose LY3298176 led to improvements in HbA1c and weight loss that were better than those seen to date with marketed diabetes drug Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO).

Lilly plans to begin the Phase III SURPASS program of LY3298176 for Type II diabetes by early 2019, and complete the program in late 2021. Lilly also said it will evaluate next steps for the candidate to treat obesity...